Drugs / Adipose-Derived Stromal Vascular Fraction
Adipose-Derived Stromal Vascular Fraction
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05857371 | Mar 2024 → Nov 2027 expected | urethral stricture | Assistance Publique Hopitaux De Marseille | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose-Derived Stromal Vascular Fraction | “autologous Adipose-Derived Stromal Vascular Fraction of Adipose Tissue (ADSVF)” NCT05857371 ↗ |
| Known as | Adipose-Derived Stromal Vascular Fraction of Adipose Tissue | “autologous Adipose-Derived Stromal Vascular Fraction of Adipose Tissue (ADSVF)” NCT05857371 ↗ |
| Known as | ADSVF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05857371 ↗ |
| Modality | Cell therapy | “experimental cell drug” NCT05857371 ↗ |
| Route | Other | “ADSVF will be administrated in fibrotic lesion during urethrotomy by the urologist” NCT05857371 ↗ |